Amylyx Pharmaceuticals (AMLX) News Today $3.98 +0.16 (+4.19%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$3.98 0.00 (-0.13%) As of 04/17/2025 04:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmApril 16 at 3:56 PM | gurufocus.comKuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law FirmApril 16 at 2:00 PM | globenewswire.comIs Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16 at 12:04 PM | msn.comExodusPoint Capital Management LP Acquires New Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)ExodusPoint Capital Management LP bought a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 106,237 shares of the company's stock, valued at approximateApril 15 at 4:21 AM | marketbeat.comWellington Management Group LLP Makes New $793,000 Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Wellington Management Group LLP purchased a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 209,708 shares of the company's stock, valued at approximately $793,000. WApril 15 at 3:31 AM | marketbeat.comAmylyx doses first participant in LUMINA trialApril 9, 2025 | markets.businessinsider.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded to "Outperform" at MizuhoMizuho upgraded shares of Amylyx Pharmaceuticals from a "neutral" rating to an "outperform" rating and set a $7.00 price objective on the stock in a research note on Monday.April 9, 2025 | marketbeat.comAmylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral SclerosisApril 9, 2025 | businesswire.comAmylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral SclerosisApril 9, 2025 | businesswire.comAmylyx upgraded to Outperform from Neutral at MizuhoApril 8, 2025 | markets.businessinsider.comPositive Report for Amylyx Pharmaceuticals Inc (AMLX) from Mizuho SecuritiesApril 8, 2025 | markets.businessinsider.comMizuho Upgrades Amylyx Pharmaceuticals (AMLX)April 8, 2025 | msn.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by MizuhoApril 8, 2025 | americanbankingnews.comAmylyx upgraded at Mizuho on potential of lead assetApril 7, 2025 | msn.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates Sells 10,896 SharesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CFO James M. Frates sold 10,896 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $37,809.12. Following the transaction, the chief financial officer now directly owns 290,988 shares in the company, valued at $1,009,728.36. This represents a 3.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.April 4, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Camille L. Bedrosian Sells 12,425 Shares of StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Camille L. Bedrosian sold 12,425 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $3.47, for a total value of $43,114.75. Following the transaction, the insider now directly owns 194,375 shares in the company, valued at approximately $674,481.25. The trade was a 6.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.April 4, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Joshua B. Cohen Sells 21,490 SharesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) CEO Joshua B. Cohen sold 21,490 shares of the stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $3.47, for a total transaction of $74,570.30. Following the transaction, the chief executive officer now owns 3,355,280 shares of the company's stock, valued at $11,642,821.60. This represents a 0.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.April 4, 2025 | marketbeat.comJames M. Frates Sells 10,896 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) StockApril 3, 2025 | insidertrades.comAmylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of "Moderate Buy" from BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating, three have issuedMarch 31, 2025 | marketbeat.comIs Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Purchases $37,000.00 in StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) Director Bernhardt G. Zeiher purchased 10,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were purchased at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at approximately $37,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.March 25, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Acquires $37,000.00 in StockMarch 25, 2025 | insidertrades.comKennondale Capital Management LLC Takes Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)Kennondale Capital Management LLC purchased a new stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 134,445 shares of the company's stock, valuedMarch 19, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Bought by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. raised its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 43.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,263,353 shares of the company's stocMarch 17, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for AMLX FY2025 Earnings?Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Equities research analysts at HC Wainwright cut their FY2025 earnings per share estimates for Amylyx Pharmaceuticals in a research report issued to clients and investors on Wednesday, March 5th. HC Wainwright analyst A. Fein now expects tMarch 10, 2025 | marketbeat.comAnalysts Offer Predictions for AMLX Q1 EarningsAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for Amylyx Pharmaceuticals in a research report issued on Wednesday, March 5th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of ($0.43) per share for the quMarch 8, 2025 | marketbeat.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of Amylyx Pharmaceuticals in a research note on Wednesday.March 6, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of "Moderate Buy" by BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been given an average rating of "Moderate Buy" by the nine analysts that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, three have issued a buy recommendation aMarch 6, 2025 | marketbeat.comAmylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...March 5, 2025 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q4 2024 Earnings Call TranscriptMarch 5, 2025 | msn.comAmylyx Pharmaceuticals Faces Challenges in Acquisition Strategy Amid RELYVRIO DiscontinuationMarch 5, 2025 | tipranks.comAmylyx Pharmaceuticals Reports 2024 Financial ResultsMarch 4, 2025 | tipranks.comAmylyx Pharmaceuticals’ Earnings Call Highlights Clinical ProgressMarch 4, 2025 | tipranks.comAmylyx reports Q4 EPS (55c) vs. 7c last yearMarch 4, 2025 | markets.businessinsider.comAmylyx files $300M mixed securities shelfMarch 4, 2025 | markets.businessinsider.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest UpdateAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) saw a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 3,380,000 shares, a growth of 30.5% from the January 31st total of 2,590,000 shares. Currently, 6.8% of the company's shares are sold short. Based on an average trading volume of 820,300 shares, the days-to-cover ratio is currently 4.1 days.March 4, 2025 | marketbeat.comAmylyx Pharmaceuticals (NASDAQ:AMLX) Announces Earnings ResultsAmylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.06).March 4, 2025 | marketbeat.comAmylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 4, 2025 | businesswire.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $13,132.35 in StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Gina Mazzariello sold 4,169 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $3.15, for a total value of $13,132.35. Following the completion of the sale, the insider now owns 134,921 shares of the company's stock, valued at approximately $425,001.15. This trade represents a 3.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.February 27, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Gina Mazzariello Sells 4,169 SharesFebruary 27, 2025 | insidertrades.comAmylyx Pharmaceuticals to Participate in Upcoming March Investor ConferencesFebruary 26, 2025 | finance.yahoo.comAmylyx Pharmaceuticals to Participate in Upcoming March Investor ConferencesFebruary 25, 2025 | businesswire.comAmylyx Pharmaceuticals: Lots Of Setbacks, Some Chances Of RecoveryFebruary 24, 2025 | seekingalpha.comAmylyx Pharmaceuticals (AMLX) to Release Quarterly Earnings on ThursdayAmylyx Pharmaceuticals (NASDAQ:AMLX) will be releasing earnings before the market opens on Thursday, February 27.February 20, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Position Lowered by abrdn plcabrdn plc lowered its position in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) by 12.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,722,805 shares of the company's stock after seFebruary 9, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Moderate Buy" by BrokeragesAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine brokerages that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation, three have issuedFebruary 9, 2025 | marketbeat.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells $12,836.22 in StockFebruary 6, 2025 | insidertrades.comAmylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in sharesFebruary 5, 2025 | msn.comInsider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells 3,678 Shares of StockAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) insider Gina Mazzariello sold 3,678 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $3.49, for a total value of $12,836.22. Following the sale, the insider now owns 139,090 shares in the company, valued at $485,424.10. This represents a 2.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.February 5, 2025 | marketbeat.com Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address AMLX Media Mentions By Week AMLX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMLX News Sentiment▼0.790.49▲Average Medical News Sentiment AMLX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMLX Articles This Week▼83▲AMLX Articles Average Week Get Amylyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AMLX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vera Therapeutics News Today Mesoblast News Today Immunocore News Today Travere Therapeutics News Today Indivior News Today Edgewise Therapeutics News Today Ocular Therapeutix News Today Calliditas Therapeutics AB (publ) News Today Evotec News Today Amphastar Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMLX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AMLX Stock Free AMLX Stock Alerts